Advanced search
Publication Cover
Acta Oncologica Volume 47, 2008 - Issue 5
Journal homepage
1,287
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib

Peter C. Trask Pfizer Inc., New London, CT, USACorrespondence[email protected]
,
Andrew G. Bushmakin Pfizer Inc., Global Research and Development, Groton, CT, USA
,
Joseph C. Cappelleri Pfizer Inc., Global Research and Development, Groton, CT, USA
,
Paul Bycott Pfizer Inc., Global Research and Development, La Jolla, CA, USA
,
Katherine Liau Pfizer Inc., Global Research and Development, La Jolla, CA, USA
&
Sinil Kim Pfizer Inc., Global Research and Development, La Jolla, CA, USA
Pages 843-851 | Received 19 Nov 2007, Published online: 08 Jul 2009

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Stavros Sfoungaristos, Konstantinos Giannitsas & Petros Perimenis. (2011) Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma. Expert Opinion on Pharmacotherapy 12:4, pages 533-547.
Read now

Articles from other publishers (14)

Masako Shomura, Tatehiro Kagawa, Haruka Okabe, Koichi Shiraishi, Shunji Hirose, Yoshitaka Arase, Kota Tsuruya, Sachiko Takahira & Tetsuya Mine. (2016) Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer 16:1.
Crossref
Andreas K.A. Gaumann, Friedemann Kiefer, Joachim Alfer, Sven A. Lang, Edward K. Geissler & Georg Breier. (2016) Receptor tyrosine kinase inhibitors: Are they real tumor killers?. International Journal of Cancer 138:3, pages 540-554.
Crossref
Patricia A. Creel. (2014) Optimizing Patient Adherence to Targeted Therapies in Renal Cell Carcinoma. Clinical Journal of Oncology Nursing 18:6, pages 694-700.
Crossref
Hideaki Miyake, Ken-ichi Harada, Taka-aki Inoue & Masato Fujisawa. (2014) Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors. Medical Oncology 31:9.
Crossref
Alyssa Fischer, Shenhong Wu, Alan L. Ho & Mario E. Lacouture. (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investigational New Drugs 31:3, pages 787-797.
Crossref
D Cella, B Escudier, B Rini, C Chen, H Bhattacharyya, J Tarazi, B Rosbrook, S Kim & R Motzer. (2013) Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer 108:8, pages 1571-1578.
Crossref
Hideaki Miyake, Ken-ichi Harada, Yuji Kusuda & Masato Fujisawa. (2011) Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib. International Journal of Clinical Oncology 18:2, pages 220-225.
Crossref
Lily P.H. Yang & Kate McKeage. (2012) Axitinib. Drugs 72:18, pages 2375-2384.
Crossref
David Cella. (2011) Beyond Traditional Outcomes: Improving Quality of Life in Patients with Renal Cell Carcinoma. The Oncologist 16:S2, pages 23-31.
Crossref
Hideaki Miyake, Toshifumi Kurahashi, Kazuki Yamanaka, Yutaka Kondo, Atsushi Takenaka, Taka‐aki Inoue & Masato Fujisawa. (2010) Impact of sorafenib on health‐related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU International 106:11, pages 1643-1647.
Crossref
Sumanta Kumar Pal & Robert A. Figlin. (2010) Targeted therapies for renal cell carcinoma: understanding their impact on survival. Targeted Oncology 5:2, pages 131-138.
Crossref
Rolf W. Sparidans, Dilek Iusuf, Alfred H. Schinkel, Jan H.M. Schellens & Jos H. Beijnen. (2009) Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography B 877:32, pages 4090-4096.
Crossref
David Cella. (2009) Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes. Cancer Treatment Reviews 35:8, pages 733-737.
Crossref
Lisa M Pickering, Linda Pyle & James MG Larkin. (2009) Sunitinib is superior to interferon α with respect to quality of life for patients with renal cell carcinoma. Nature Clinical Practice Oncology 6:1, pages 6-7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.